Menu

2020年去纤苷在国内的价格

Author: Medicalhalo
Release time: 2025-10-19 11:44:20

On March 30, 2016, the FDA approved defibrotide (defiteli) for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), and renal or pulmonary dysfunction following hematopoietic stem cell transplantation (HSCT).

In clinical trials, while heparin was used to prevent diseases such as hepatic veno-occlusion, it greatly increased the risk of bleeding, while defibrotide alone or in combination with heparin had a very low incidence of side effects and achieved good results in preventing HVOD. In a phase III multi-center randomized clinical trial completed in Europe, a total of 356 stem cell transplant patients were recruited. The incidence of hepatic vein occlusion 30 days after transplantation was compared. It was found that 2 of 180 patients in the defibrotide group developed hepatic vein occlusion, accounting for 12%; 35 of 176 patients in the control group developed hepatic vein occlusion, accounting for 20%. 

Corbacioglu et al. analyzed the value of defibrotide in the treatment of HVOD in children in a retrospective clinical study, which included 45 patients with HVOD after HSCT who were <20 years old, with a median age of 8.2 years (0.2-20 years). The dose of defibrotide is 10~110 mg/kg per day, intravenous infusion, and the median use time is 17 days (1-83 days). The results showed that the complete response (CR) rate was 76%, and the overall survival (OS) rate 1,00 days after transplantation was 64%. Among them, the CR rate of 22 SHVOD patients was 50%, and the OS rate 100 days after transplantation was 36%. This study not only confirmed the effectiveness of defibrotide in treating HVOD in children, but also showed that the addition of other drugs to treat HVOD does not affect the efficacy of defibrotide in treating HVOD. So, what is the domestic price of defibrotide (defiteli sodium) in 2020? Let's take a look.

The latest price of defibrotide (defiteli, defiteli): Defibrotide (defiteli, defiteli) has not yet been launched in my country. Medical Travel has learned that the price of defibride (defiteli, defiteli) is 28,000$.

[ 免责声明 ]  本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。